Book a demo

Chemical intelligence powered by cypris.ai

Semaglutide

18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid · also: Wegovy, Ozempic, Rybelsus, Kayshild, semaglutida, Sermaglutide

FormulaC187H291N45O59
Mol. weight4113.641
PubChem CID56843331
InChIKeyDLSWIYLPEUIQAV-CCUURXOWSA-N
SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
8,537Patents
1,345Research papers
4,093Patents - last 3 years
835Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Sanofi SA881
2Novo Nordisk AS449
3Sanofi Aventis Deutschland GmbH351
4SHL Medical AG284
5Sanofi Aventis France270
6Pfizer Inc268
7Pfizer Corp SRL251
8Merck Sharp & Dohme LLC225
9Boehringer Ingelheim International GmbH174
10Gilead Sciences Inc167

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations5,625
2A61PTherapeutic activity (drug indications)5,273
3C07KPeptides2,216
4A61MDevices for introducing media into the body1,931
5C07DHeterocyclic compounds1,889
6C12NMicroorganisms, enzymes608
7G16HDigital health, healthcare informatics313
8C07BGeneral methods of organic chemistry300
9C07CAcyclic and carbocyclic compounds294
10G01NInvestigating / analysing materials275

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Preparation method of semaglutide2015HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD.32
Solid synthetic method of semaglutide2014Hybio Pharmaceutical Co., Ltd.23
High-expression semaglutide precursor recombinant engineering bacterium and construction method thereof2021Beijing Huizhiheng Biological Technology Co Ltd18
Semaglutide purifying method2016Hybio Pharmaceutical Co., Ltd.17
Preparation method of semaglutide and intermediate of semaglutide2016Hybio Pharmaceutical Co., Ltd.11

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Diabetes Treatment and Management6
2Advanced Drug Delivery Systems1
3Intraoperative Neuromonitoring and Anesthetic Effects1
4Pancreatic and Hepatic Oncology Research1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Ildiko LingvayThe University of Texas Southwestern Medical Center33
2Søren RasmussenNovo Nordisk (Denmark)21
3Melanie J. DaviesUniversity of Leicester18
4Subodh VermaSt. Michael's Hospital17
5A. Michael LincoffCleveland Clinic Lerner College of Medicine15
6Andrei‐Mircea CatarigNovo Nordisk (Denmark)15
7Barry A. BorlaugMayo Clinic12
8Barnaby HuntFreiwillige Akademische Gesellschaft11
9Mikhail KosiborodSaint Luke's Hospital9
10Stephen C. BainSwansea University9

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

TitleYearCited byTopic
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes20166759Diabetes Treatment and Management
Once-Weekly Semaglutide in Adults with Overweight or Obesity20214646Diabetes Treatment and Management
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes20232745Diabetes Treatment and Management
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes20211956Diabetes, Cardiovascular Risks, and Lipoproteins
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis20201947Liver Disease Diagnosis and Treatment

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of Semaglutide?

Semaglutide has the molecular formula C187H291N45O59 with a molecular weight of 4113.641 g/mol. Its InChI Key is DLSWIYLPEUIQAV-CCUURXOWSA-N. The compound is also known by several commercial and generic names including Wegovy, Ozempic, Rybelsus, and Kayshild.

Which organizations hold the most patents related to Semaglutide?

Sanofi SA leads with 881 patents, followed by Novo Nordisk AS with 449 patents and Sanofi Aventis Deutschland GmbH with 351 patents. Other significant patent holders include SHL Medical AG, Sanofi Aventis France, Pfizer Inc, Pfizer Corp SRL, Merck Sharp & Dohme LLC, Boehringer Ingelheim International GmbH, and Gilead Sciences Inc.

What are the most cited research papers on Semaglutide?

The most highly cited paper is 'Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes' from 2016 with 6,759 citations. This is followed by 'Once-Weekly Semaglutide in Adults with Overweight or Obesity' from 2021 with 4,646 citations, and 'Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes' from 2023 with 2,745 citations.

What is the trend in patent filings for Semaglutide over recent years?

Patent filings have grown substantially, with 174 patents in 2016 increasing to 1,823 in 2024. The most significant growth occurred from 2021 onwards, with 523 patents filed in 2021 rising to 1,205 in 2022 and 1,461 in 2023. Of the total 8,537 patents on record, 4,093 were filed in the last three years.

What are the primary patent classification areas for Semaglutide?

The leading CPC subclass is A61K (Preparations for Medical, Dental, or Toilet Purposes) with 5,625 patents, followed by A61P (Specific Therapeutic Activity of Chemical Compounds or Preparations) with 5,273 patents. Other significant classifications include C07K (Organic Chemistry - Peptides) with 2,216 patents, A61M (Medical Devices) with 1,931 patents, and C07D (Organic Chemistry - Heterocyclic Compounds) with 1,889 patents.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial